Dry Eye Syndromes: Clinical Trials

1634 trials for Dry Eye Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1034 completed, 224 unknown, 137 recruiting, 82 not yet recruiting. 561 Not applicable, 296 Phase 2, 230 Phase 4, 196 Phase 3, 118 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable561Completed 362, Unknown 85, Recruiting 34, Not yet recruiting 25, Terminated 20, Active not recruiting 15, Withdrawn 14, Enrolling by invitation 5, Suspended 1
Phase 2296Completed 206, Unknown 32, Recruiting 18, Terminated 17, Not yet recruiting 12, Withdrawn 7, Active not recruiting 3, Enrolling by invitation 1
Phase 4230Completed 133, Unknown 33, Recruiting 22, Not yet recruiting 14, Terminated 12, Withdrawn 9, Active not recruiting 5, Enrolling by invitation 2
Phase 3196Completed 153, Unknown 19, Recruiting 8, Active not recruiting 5, Not yet recruiting 4, Terminated 4, Withdrawn 2, Suspended 1
Phase 1118Completed 70, Recruiting 16, Unknown 16, Not yet recruiting 8, Terminated 4, Withdrawn 3, Active not recruiting 1
Early Phase 127Completed 9, Not yet recruiting 5, Recruiting 5, Unknown 3, Suspended 2, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow this condition Literature Review of Dry Eye Syndromes trials Research Report on Dry Eye Syndromes

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease
RCI001 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye
Phase 2Not yet recruitingRudacure2002027-09-012026-06-04
Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops - Dry Eye Syndromes
Not applicableWithdrawnUniversity of Rochester2027-01-012026-07-16
Penn SICCA Follow-up Study
Dry Eye, Sjogren's Syndrome
Not yet recruitingUniversity of Pennsylvania2202027-01-012026-03-02
Effect of Behavioral Intervention (Baduanjin Alone or Laughter Exercise Plus Artificial Tears) Versus Artificial Tear on Dry Eye Disease: a Randomised Controlled Trial
Baduanjin, Laughter exercise, Artificial tears - Dry Eye Disease (DED)
Not applicableNot yet recruitingZhongshan Ophthalmic Center, Sun Yat-sen University5402027-01-012026-04-13
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 3Not yet recruitingBristol-Myers Squibb23002026-12-312026-09-03
Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease
Infliximab 0.1%, Loteprednol - Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis
Phase 2Not yet recruitingInstituto de Oftalmología Fundación Conde de Valenciana382026-12-012026-06-26
Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren Syndrome
exosomes derived from human umbilical cord mesenchymal stem cells, Mesenchymal Stem Cells (MSC), Placebo - Sjogren Syndrome, Xerostomia
Phase 2Not yet recruitingBanu Erkal302026-12-012026-09-24
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2Not yet recruitingPeking University Third Hospital92026-11-012026-09-23
R-2487 in Patients With Sjogren's Syndrome (SS)
R-2487 - Sjogren's Syndrome, Sjögren
Phase 1Not yet recruitingRise Therapeutics LLC362026-11-012026-09-28
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 1Not yet recruitingBristol-Myers Squibb602026-10-302026-10-14
Effectiveness of an Oral Exercise Program for Xerostomia in Patients With Sjögren Disease
Oral exercise - Sjogren Syndrome
Not applicableNot yet recruitingNazli Elif Nacar562026-10-262026-10-08
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Bedside quantitative sensory testing - Rheumatic Diseases, Lupus Erythematosus, Systemic
Not yet recruitingNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2252026-10-262026-10-21
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
Part A - Placebo for IBI355, Part B -Telitacicept, PartB -Placebo for Telitacicept - Sjögren's Disease
Phase 2Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.1982026-10-152026-09-23
Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
acoltremon 0.003% - Dry Eye, Contact Lens Discomfort
Phase 4Not yet recruitingEye Research Associates, LLC502026-10-102026-10-08
Exploratory Study of the Efficacy of HuMoSCs (Human Monocyte-derived Suppressor Cells) on Glandular Involvement in Sjögren's Syndrome
Blood sample, Salivary gland biopsy - Sjogren's Syndrome, Autoimmune Diseases
Not applicableNot yet recruitingCentre Hospitalier Universitaire Dijon202026-10-102026-10-06
Switching From Preserved Glaucoma Therapy to Preservative-Free ZOLYMBUS
preservative free ZOLYMBUS™ 0.01%. - Eye Drops Self-instillation, Glaucoma
Phase 4Not yet recruitingSouthern College of Optometry402026-10-052026-09-28
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients
Meibomian Gland Dysfunction, Dry Eye Syndromes
Not yet recruitingAssiut University1502026-10-012026-09-09
Study of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs
Eye Exams, Ocular Biometry and Aberrometry, Wearing a Smartwatch - Myopia, Dry Eye Disease (DED)
Not applicableNot yet recruitingEssilor International1202026-10-012026-09-28
BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
BL1107 - Dry Eye Disease
Phase 2Not yet recruitingBausch & Lomb Incorporated202026-10-012026-08-21
Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain
acoltremon ophthalmic solution 0.003% - Ocular Pain, Dry Eye
Phase 4Not yet recruitingUniversity of South Florida282026-10-012026-10-06

Showing 20 of 1634. Sign in to see all of them.

Narrower conditions

Sjogren's Syndrome (318)  ·  Meibomian Gland Dysfunction (96)  ·  Keratoconjunctivitis Sicca (85)  ·  Lupus Erythematosus, Systemic (70)  ·  Arthritis, Rheumatoid (47)  ·  Xerostomia (47)  ·  Scleroderma, Systemic (44)  ·  Autoimmune Diseases (42)  ·  Myositis (32)  ·  Cataract (30)  ·  Xerophthalmia (29)  ·  Corneal Diseases (28)  ·  Scleroderma, Diffuse (20)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (19)

Broader conditions

Lacrimal Apparatus Diseases (1628)  ·  Eye Diseases (1618)  ·  Immune System Diseases (351)  ·  Skin and Connective Tissue Diseases (340)  ·  Mouth Diseases (327)  ·  Stomatognathic Diseases (327)  ·  Musculoskeletal Diseases (324)  ·  Connective Tissue Diseases (321)  ·  Joint Diseases (321)  ·  Rheumatic Diseases (316)  ·  Salivary Gland Diseases (316)  ·  Arthritis (313)  ·  Autoimmune Diseases (288)  ·  Xerostomia (275)

Interventions

Ophthalmic Solutions (47)  ·  Lubricant Eye Drops (44)  ·  Cyclosporins (43)  ·  Cyclosporine (32)  ·  lifitegrast (31)  ·  Hyaluronic Acid (26)  ·  Carboxymethylcellulose Sodium (16)  ·  Loteprednol Etabonate (15)  ·  Sodium Chloride (13)  ·  Calcium Dobesilate (12)  ·  Nasal Sprays (12)  ·  Propylene Glycol (12)  ·  rebamipide (12)  ·  Intense Pulsed Light Therapy (11)  ·  diquafosol (10)

Sponsors

Alcon Research (87)  ·  Allergan (43)  ·  Medical University of Vienna (24)  ·  Bausch & Lomb Incorporated (23)  ·  Singapore National Eye Centre (21)  ·  Novartis Pharmaceuticals (18)  ·  He Eye Hospital (17)  ·  National Institute of Dental and Craniofacial Research (NIDCR) (17)  ·  Peking University Third Hospital (17)  ·  University of Alabama at Birmingham (15)  ·  University of Waterloo (15)  ·  Innovative Medical (14)  ·  Aldeyra Therapeutics, Inc. (13)  ·  Laboratoires Thea (13)  ·  Laboratorios Sophia S.A de C.V. (13)

Countries

United States (627)  ·  China (152)  ·  France (98)  ·  South Korea (72)  ·  Italy (67)  ·  Taiwan (63)  ·  Canada (62)  ·  Spain (60)  ·  United Kingdom (53)  ·  Austria (43)  ·  Germany (40)  ·  Mexico (38)  ·  Australia (35)  ·  Turkey (Türkiye) (35)  ·  Brazil (34)

Top investigators

Gail Torkildsen, MD (17)  ·  Louis Tong, PhD (13)  ·  Pedram Hamrah, MD (8)  ·  Ching-Mao Chang, M.D., Ph.D. (6)  ·  John Hovanesian, MD (6)  ·  Emmanuel Eric Pazo (5)  ·  Lyndon Jones, PhD, FCOptom (5)  ·  Sandeep Jain, MD (5)  ·  Sonja Kroesser, PhD (5)

Results publications

PMID 12649304, PMID 12823990, PMID 25179431, PMID 32280196, PMID 36729473, PMID 9778415, PMID 27929721, PMID 28736340, PMID 39839752, PMID 11237914, PMID 11879137, PMID 14508260, PMID 15161834, PMID 15286669, PMID 15832184, PMID 18848318, PMID 20973888, PMID 23445780, PMID 23665202, PMID 27119078, PMID 27294831, PMID 27893109, PMID 28190580, PMID 28280298, PMID 28319106, PMID 28475124, PMID 28736335, PMID 29075094, PMID 29671255, PMID 29731019, PMID 31518657, PMID 31800960, PMID 31834617, PMID 34707360, PMID 37096956, PMID 42470519, PMID 10815152, PMID 15090417, PMID 15502479, PMID 17102664, PMID 17216085, PMID 17508121, PMID 20631232, PMID 20735287, PMID 21280008, PMID 21750611, PMID 22670856, PMID 26365210, PMID 27055211, PMID 27445067

NIH funding

2018 (6), 2015 (4), 2016 (4), 2023 (4), 2025 (4), 2019 (3), R01EY022038 (1), R01EY022663 (1), R01EY024966 (1), R01EY038655 (1), R33NS113341 (1), R34EY017626 (1), R37AI049660 (1), U01NS106845 (1), U10EY022879 (1)